FINAL Symposium Agenda

2024 Global Labeling & Regulatory Symposium

Developed and presented in partnership with Opus Regulatory

October 8 - 9, 2024 Kimpton Hotel Monaco – Washington, DC

Course Description

This is a one-of-a-kind comprehensive labeling education symposium that explores both fundamental labeling skills and specialized concepts, including current events and new regulatory initiatives. Throughout the two-day program, global experts from big pharma and small pharma will lead several dynamic sessions; faculty for this program also include current and former FDA representatives, academics, and consultant presenters. The program features a blend of interactive presentations, panel discussions, case studies, and collaborative sessions, each meticulously planned to provide the best experience for symposium participants.

Course Day 1: Tuesday, October 8, 2024		<u>#</u>
7:30 – 8:30 AM	Check in & Continental Breakfast	
8:30 – 8:45 AM	Welcome Remarks	
8:45 – 10:10 AM	Establishing Labeling Governance and Process	S1
8:50 – 9:10 AM	Presentation: Small Pharma – No Labeling Presence	
	Jody L Roth, PMP, RAC Vice President Global Regulatory Affairs Immunovant	
9:10 – 9:30 AM	Presentation: Medium Pharma – Establishing Labeling Model	
	Christina McGahan Senior Director, Global Labeling Otsuka Pharmaceutical Development & Commercialization	
9:30 – 9:50 AM	Presentation: Large Pharma – "Well Oiled Machine"	
	Kelly Treonze Executive Director, Global Labeling Therapeutic Areas Merck & Co., Inc.	
9:50 – 10:10 AM	Panel Q&A	
10:10 – 10:25 AM	Stretch Break	

 $\ensuremath{\mathbb{C}}$ 2024 Pharmaceutical Education and Research Institute, Inc. (PERI)



Course Day 1: Tuesday, October 8, 2024 continued

10:25 – 11:45 AM	Patient-Reported Outcomes & Real-World Evidence in Labeling	S2
10:30 – 10:50 AM	Presentation: Case Study: FDA Review of RWE in Breast Cancer Therapy	
	Catherine Lerro, PhD, MPH Senior Pharmacoepidemiologist Oncology Center of Excellence US Food and Drug Administration	
10:50 – 11:10 AM	Presentation: Academic Perspective: Patient Reported Outcomes in Labeling	
	Ari Gnanasakthy, MBA, MSc Principal Scientist, Patient-Centered Outcome Assessment RTI Health Solutions	
11:10 – 11:30 AM	Presentation: FDA Perspective/Update on Patient Reported Outcomes	
	Vishal Bhatnagar, MD Associate Director, Patient Outcomes Oncology Center of Excellence US Food and Drug Administration	
11:30 AM – 11:45 AM	Panel Q&A	
11:45 – 11:55 AM	Stretch Break	
11:55 AM – 1:15 PM	Labeling Lifecycle Concepts	S3
12:00 – 12:20 PM	Presentation: What is End-to-End Labeling – How Does It Evolve?	
	Vijay Sammeta, MD, MBA Head, Global Regulatory Affairs Labeling Daiichi Sankyo	
12:20 – 12:40 PM	Presentation: Deviation Management and Tracking Tool	
	Kelly Treonze Executive Director, Global Labeling Therapeutic Areas Merck & Co., Inc.	
12:40 – 1:00 PM	Presentation: Preparing for the World of E-Labeling	
	<mark>Sima Desai</mark> Senior Director Global Labeling Sanofi	
1:00 – 1:15 PM	Panel Q&A	
1:15 – 2:30 PM	Networking Luncheon	

Course Day 1: Tuesday, October 8, 2024 continued

2:30 – 3:50 PM	The Importance of Development Labeling		S4
2:35 – 2:55 PM	Presentation: Labeling Perspective on TPL – <i>k responsible, How is it done (example)</i>	When should it start, Who is	
	Vijay Sammeta, MD, MBA Head, Global Regulatory Affairs Labelin Daiichi Sankyo	g	
2:55 – 3:15 PM	Presentation: TPL in Phase II – Impact to Prote	ocol Development and SAP	
	Heather Hammond, BPharm, MSc Director, Regulatory Labeling Regeneron		
3:15 – 3:35 PM	Presentation: Label as Driver Case Study – The How did we start and where did we land?	e evolution of label messaging.	
	Thomas Kilker Director, Regulatory Affairs Labeling Jazz Pharmaceuticals		
3:35 – 3:50 PM	Panel Q&A		
3:50 – 4:05 PM	Stretch Break		
4:05 – 5:25 PM	FDA Key Labeling Initiatives		S5
4:10 – 4:40 PM	Presentation: Oncology Center of Excellence (Initiatives (Project Renewal, Oncology Labeling		
	William Pierce, PharmD, MPH, BCPS Associate Director, Oncology Labeling Oncology Center of Excellence US Food and Drug Administration		
4:40 – 5:25 PM	FDA Panel Discussion / Q&A		
	Doris Auth Vishal Bhatnagar, MD Catherine Lerro, PhD, MPH William Pierce, PharmD, MPH, BCPS US Food and Drug Administration		
5:25 – 5:30 PM	<u>Closing Remarks: Day 1</u>		
6:00 – 7:30 PM *Optional	Evening Networking Reception	Paris Ballroom, Hotel Monaco	

Join us for drinks and hors d'oeurves after a long day of learning! Relax and mingle with participants and faculty, as well as connect with representatives from Docuvera, one of our symposium sponsors.

Course Day 2: Wednesday, October 9, 2024

7:30 – 8:30 AM	Check in & Continental Breakfast	
8:30 – 8:40 AM	Welcome Remarks	
8:40 – 10:00 AM	Labeling for Challenging Populations	S 6
8:45 – 9:05 AM	Presentation: Pediatrics Case Study - Impact to Labeling	
	Laurie Cooker, PhD Director, Strategic Global Labeling AbbVie	
9:05 – 9:25 AM	Presentation: Rare Disease Case Study	
	Kathy Bradley Global Labeling Director Astra Zeneca	
9:25 - 9:45 AM	Presentation: Companion Diagnostics – Global Case Study	
	Heather Hammond, BPharm, MSc Director, Regulatory Labeling Regeneron	
9:45 – 10:00 AM	Panel Q&A	
10:00 – 10:20 AM	Morning Break	
10:20 – 11:40 AM	Oncology Safety Labeling	S 7
10:25 – 10:55 AM	Presentation: Oncology Overview of FDA Adverse Reaction Guidance for SARs, Dosage Modifications, and Low Incidence Adverse Reactions	
	William Pierce, PharmD, MPH, BCPS Associate Director, Oncology Labeling Oncology Center of Excellence, US Food and Drug Administration	
10:55 – 11:25 AM	Presentation: Local Country Labeling Impact to Company Core Data Sheet	
	Mark A. Smith Director, Global Labeling Strategy Bristol Myers Squibb	

11:25 - 11:40 AM Panel Q&A

Course Day 2: Wednesday, October 9, 2024 continued

_

11:40 – 11:50 AM	Stretch Break	-
11:50 AM – 1:10 PM	Instructions for Use Labeling	S 8
11:55 AM – 12:25 PM	Presentation: IFU as Global Labeling Document and Human Factor Testing Gerrit Nijveldt Principal Labeling Consultant Opus Regulatory, Inc.	
12:25 – 12:55 PM	Presentation: Instructions for Use Labeling Case Study Mike Fahmy Executive Director Otsuka Pharmaceutical Development & Commercialization	
12:55 – 1:10 PM	Panel Q&A	
1:10 – 2:25 PM	Networking Luncheon	
2:25 – 4:00 PM	Label Negotiations	S9
2:30 – 3:00 PM	Presentation: FDA Perspective: How are labeling negotiations managed, Advice to sponsor, Roles and responsibilities Doris Auth, PharmD Associate Director for Labeling Oncology Center of Excellence US Food and Drug Administration	
3:00 – 3:30 PM	Presentation: Industry perspective: Preparing and managing label negotiations, best practices, and common considerations Jamie Park Global Labeling Lead Pfizer	
3:30 – 3:50 PM	Panel Q&A	
3:50 – 4:00 PM	Program Wrap Up & Conclusion	